Cns Tumors clinical trials

Explore recruiting cns tumors clinical trials.

Recruiting cns tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cns Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II trial aiming to assess the safety and clinical activity of Tarlatamab in combination with metronomic Temozolomide in adolescents and adults’ patients with high grade brain tumors

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors.

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

France, Italy, Spain, Hungary

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Single-arm, multicenter Phase I/Ib study of avelumab + lenvatinib in children with primary CNS tumors

France, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX -101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or who have no Satisfactory Treatment Options

Germany, Italy, France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies (INFORM2-NivEnt)

Austria, Sweden, Germany, Netherlands, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Cns Tumors trials by city

Cns Tumors in Toronto Cns Tumors in Vancouver Cns Tumors in Montreal Cns Tumors in Calgary Cns Tumors in Edmonton Cns Tumors in Ottawa Cns Tumors in Winnipeg Cns Tumors in Quebec City Cns Tumors in Hamilton Cns Tumors in Kitchener Cns Tumors in London Cns Tumors in Halifax Cns Tumors in New York Cns Tumors in Los Angeles Cns Tumors in Chicago Cns Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease